Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Expert review of pharmacoeconomics and outcomes Research: high impact articles from 2025. 药物经济学和结果研究专家综述：2025年以来高影响力文章。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-20 DOI: 10.1080/14737167.2026.2752198

Tamas Agh, Mickael Hiligsmann, Carolyn Gotay, Jayashri Sankaranarayanan, Carlo Lazzaro, Katarzyna Kolasa, Steven Simoens, Lieke Maas, Ryan Gilroy

引用次数: 0

Assessing health related quality of life of patients on maintenance hemodialysis in north-western Morocco. 评估摩洛哥西北部维持性血液透析患者的健康相关生活质量

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-20 DOI: 10.1080/14737167.2026.2753082

Rania Mourchid, Amal Yassine, Yahia Cherrah, Samira Serragui

{"title":"Assessing health related quality of life of patients on maintenance hemodialysis in north-western Morocco.","authors":"Rania Mourchid, Amal Yassine, Yahia Cherrah, Samira Serragui","doi":"10.1080/14737167.2026.2753082","DOIUrl":"https://doi.org/10.1080/14737167.2026.2753082","url":null,"abstract":"Background: This study evaluated health-related quality of life (HRQoL) differences between public (N = 61) and private (N = 61) sector hemodialysis patients in Morocco using Moroccan and French EQ-5D-5 L value sets.Methods: EQ-5D-5 L dimensions, utility index, and Visual Analog Scale (EQ-VAS) scores were compared between sectors through a bivariate analysis HRQoL determinants were identified via Generalized Linear Model (GLM) multivariable regression, adjusting for socio-demographic and clinical covariates.Results: Private sector patients reported higher 'no problem' rates in mobility (45.9% vs. 19.7%), self-care (34.4% vs. 18.0%), usual activities (34.4% vs. 6.6%), and pain/discomfort (31.1% vs. 11.5%). Median Moroccan utility scores were significantly higher in private vs. public sectors (0.79 vs. 0.48, p = 0.003), mirrored by French scores (0.85 vs. 0.63, p > 0.001) and EQ-VAS (median: 72 vs. 70, p > 0.001). In multivariable GLM regression, the treatment sector was not an independent predictor (beta = -0.128, p = 0.345). Instead, employment status (beta = 0.302, p = 0.035) exhibited significantly higher health-related quality of life, whereas lower weekly dialysis frequency (beta = -0.362, p = 0.003) independently predicted lower HRQoL.Conclusion: HRQoL contrasts among Moroccan hemodialysis patients highlight urgent needs to manage fatigue and encourage structured physical and social participation.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility of expanded hypertension screening and treatment among adults covered by Peru's Seguro Integral de Salud: a Markov model using national data. 秘鲁Seguro integral de salud覆盖的成人中扩大高血压筛查和治疗的成本效用：使用国家数据的马尔可夫模型。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-18 DOI: 10.1080/14737167.2026.2751401

Víctor Juan Vera-Ponce, Jhosmer Ballena-Caicedo

{"title":"Cost-utility of expanded hypertension screening and treatment among adults covered by Peru's Seguro Integral de Salud: a Markov model using national data.","authors":"Víctor Juan Vera-Ponce, Jhosmer Ballena-Caicedo","doi":"10.1080/14737167.2026.2751401","DOIUrl":"10.1080/14737167.2026.2751401","url":null,"abstract":"Background: We assessed the cost-utility of expanding hypertension screening, diagnosis, and treatment among adults covered by Peru's Seguro Integral de Salud (SIS).Research design and methods: Analyses assembled in May 2026 used a 10-year cohort Markov model parameterized with the 2024 Peruvian Demographic and Family Health Survey (ENDES), SIS administrative data for 2022-2024, and published parameters. Universal and risk-targeted scenarios were compared with population-specific usual care, using S/ 25,007 per quality-adjusted life-year (QALY).Results: The baseline sample included 6,098 adults aged 40-74 years; hypertension prevalence was 28.9%. Universal 80-80-80 expansion averted 60.7 cardiovascular events and 6.1 cardiovascular deaths and gained 51.3 QALYs per 100,000 eligible adults. Incremental cost was S/ 7,784,979, with an incremental cost-effectiveness ratio (ICER) of S/ 151,686/QALY. The scenario targeting 10-year cardiovascular risk ≥10% had an ICER of S/ 60,171/QALY in its eligible subgroup.Conclusions: All scenarios exceeded the threshold. Lower targeted-scenario ICERs concern different eligible populations. Estimates depend on modeled effects, the 10-year horizon, and exclusion of event-related savings.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced non-small cell lung cancer: an updated analysis. 阿米伐他单抗+拉泽替尼和奥西替尼+化疗与奥西替尼单药治疗一线egfr突变晚期非小细胞肺癌的成本效益：最新分析

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-15 DOI: 10.1080/14737167.2026.2746857

Pooja Gokhale, Joshua Caballero, Niying Li, Lorenzo Villa Zapata

{"title":"Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced non-small cell lung cancer: an updated analysis.","authors":"Pooja Gokhale, Joshua Caballero, Niying Li, Lorenzo Villa Zapata","doi":"10.1080/14737167.2026.2746857","DOIUrl":"10.1080/14737167.2026.2746857","url":null,"abstract":"Introduction: Osimertinib, amivantamab plus lazertinib, and osimertinib plus chemotherapy are the recommended first-line treatment options for EGFR exon 19 deletion or exon 21 L858R-mutated non-small cell lung cancer (NSCLC). This study evaluated the cost-effectiveness of these options from a United States payer perspective.Methods: A partitioned survival model compared the combination strategies to osimertinib monotherapy over a lifetime horizon, using clinical efficacy data from MARIPOSA and FLAURA2 trials. Direct medical costs and health state utilities were obtained from published sources. One-way and probabilistic sensitivity analyses assessed model robustness, using a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) or life year (LY) gained.Results: Amivantamab plus lazertinib yielded higher total discounted costs ($1,219,207), QALYs (2.64), and LYs (3.80) compared with osimertinib monotherapy ($807,707; 2.10 QALYs; 3.00 LYs), with an incremental cost-effectiveness ratio (ICER) of $756,638/QALY in the MARIPOSA analysis. In the FLAURA2 analysis, osimertinib plus chemotherapy showed higher costs ($963,033), QALYs (2.81), and LYs (3.92) compared with osimertinib monotherapy ($662,520; 2.45 QALYs; 3.39 LYs), yielding an ICER of $829,930/QALY.Conclusion: Neither combination strategy is cost-effective compared to osimertinib monotherapy for first-line EGFR-mutated advanced NSCLC from the US payer perspective.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning in comparative effective research of pharmacological interventions: a scoping review. 机器学习在药物干预比较有效研究中的应用：范围综述。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-15 DOI: 10.1080/14737167.2026.2746821

Zhen Wang, Bijan J Borah

{"title":"Machine learning in comparative effective research of pharmacological interventions: a scoping review.","authors":"Zhen Wang, Bijan J Borah","doi":"10.1080/14737167.2026.2746821","DOIUrl":"10.1080/14737167.2026.2746821","url":null,"abstract":"Introduction: Machine learning (ML) is rapidly transforming the evaluation of the comparative effectiveness research (CER) of pharmacological interventions. It offers an attractive data-driven alternative to traditional statistical causal inference methods for estimating heterogeneous and individualized treatment effects and is particularly well-suited for high-dimensional real-world data. While a variety of ML algorithms have been applied in CER, methodological challenges and limitations remain, and recommendations for conducting, reporting, and evaluating such studies have only recently been proposed.Areas covered: This paper conducts a scoping review of ML approaches used in CER for pharmacological interventions. We searched multiple databases from January 2020 to January 2026, supplemented by reference mining, and included 28 primary studies. We focused on research topics, ML methodologies, reporting, validity, and robustness of the findings, and appraised risk of bias.Expert opinion: Although the use of ML methods in CER of pharmacologic intervention is relatively recent, it is expanding and consolidating around a few specific methods, notably doubly robust estimators paired with ensemble learners. However, methodological rigor and reporting consistency remain uneven, yielding a moderate risk of bias. Standardized methods, transparent reporting, and dedicated appraisal tools are needed before these approaches can reliably inform research, clinical practice, and policy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decision analysis study. 定义复发/难治性多发性骨髓瘤CAR-T治疗基于结果的管理进入协议的价值标准：一项多标准决策分析研究

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-14 DOI: 10.1080/14737167.2026.2739076

María Victoria Mateos Manteca, José Luis Poveda Andrés, Albert Oriol Rocafiguera, Vicente Escudero-Vilaplana, José Luis Trillo Mata, Pedro Gómez Pajuelo, Alberto Arribas Ruiz, Teresa Domínguez Lubillo, Neus Vidal-Vilar, Asís Ariznavarreta Martín

{"title":"Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decision analysis study.","authors":"María Victoria Mateos Manteca, José Luis Poveda Andrés, Albert Oriol Rocafiguera, Vicente Escudero-Vilaplana, José Luis Trillo Mata, Pedro Gómez Pajuelo, Alberto Arribas Ruiz, Teresa Domínguez Lubillo, Neus Vidal-Vilar, Asís Ariznavarreta Martín","doi":"10.1080/14737167.2026.2739076","DOIUrl":"10.1080/14737167.2026.2739076","url":null,"abstract":"Background: This study aimed to identify and prioritize criteria for designing and monitoring outcomes-based managed entry agreements (MEAs) for chimeric antigen receptor T-cell (CAR-T) therapy in relapsed/refractory multiple myeloma (RRMM), from the perspective of healthcare professionals and decision-makers.Research design and methods: A structured MCDA-informed expert weighting exercise was conducted using an adapted EVIDEM framework. The study comprised two phases: a) selection and structuring of criteria through a targeted literature review and scientific committee (SC) consensus; and b) nonhierarchical weighting of criteria and sub-criteria by a multidisciplinary expert group (n = 19) of hospital pharmacists, physicians, and evaluators/decision-makers.Results: Twelve criteria were identified. Following SC discussion, five criteria were selected for weighting: efficacy, safety, patient-reported outcomes, treatment cost, and other direct medical costs. Among the weighted sub-criteria, overall survival (OS) and progression-free survival (PFS) achieved the highest scores, with mean values of 4.21 (95% CI: 3.68-4.74) and 4.05 (95% CI: 3.52-4.58), respectively.Conclusions: In this structured MCDA-informed expert weighting exercise, OS and PFS were identified as the highest-priority value criteria for designing and monitoring outcomes-based MEAs for CAR-T therapies in RRMM. These findings may support feasible, evidence-based reimbursement models but require validation in larger and more diverse stakeholder groups.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The presence of prior-effects of the Medicaid expansion on drug prescription. 医疗补助扩大对药物处方的影响。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-12 DOI: 10.1080/14737167.2026.2746156

Andrew Kim, Taisuke Sadayuki

{"title":"The presence of prior-effects of the Medicaid expansion on drug prescription.","authors":"Andrew Kim, Taisuke Sadayuki","doi":"10.1080/14737167.2026.2746156","DOIUrl":"https://doi.org/10.1080/14737167.2026.2746156","url":null,"abstract":"Background: This study examines whether states implementing the 2014 ACA Medicaid expansion experienced prior changes in physician Medicare Part D prescribing patterns compared with non-expansion states, evaluating potential anticipatory behavioral adaptations.Research design and methods: Utilizing provider-year panel data from ProPublica's Medicare Part D Prescriber dataset (2011-2016), we implement an event-study difference-in-differences framework across a geographically restricted sample of adjacent expansion/non-expansion border counties. Key physician-level outcomes include total drug costs, low-income subsidy (LIS) claims, non-LIS claims, beneficiary age structures, and brand-name shares.Results: In preferred border-county models, expansion-state physicians exhibited significantly higher pre-implementation baselines relative to 2013 for log total cost (2011: 3.334, 95% CI [1.441, 5.227], p < 0.01; 2012: 2.923, 95% CI [1.714, 4.132], p < 0.01) and log non-LIS claims, showing a narrowing pre-reform gap. Conversely, LIS claims rose significantly only post-implementation in 2015 (2.112, 95% CI [0.413, 3.811], p < 0.05) and 2016 (3.000, 95% CI [0.738, 5.262], p < 0.01).Conclusions: Medicaid policy shifts alter clinician expectations and prescribing behavior prior to formal execution. However, evaluations must be qualified by the data's reliance on Medicare Part D files rather than total historical payer mixes.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of microaxial flow pump versus standard of care in the management of Cardiogenic shock in Spain. 西班牙心源性休克治疗中微轴流泵与护理标准的成本效益比较。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-11 DOI: 10.1080/14737167.2026.2743886

Rut Andrea, Alfonso Jurado-Román, Sandra O Rosillo, Juan Bustamante-Munguira, Jose F Diaz, Maria Generosa Crespo-Leiro, Rocío González-Alonso Del Hoyo, Itziar Oyagüez, Nuria Garcia, Lorine Foux, Stylianos Tsintzos, Maria Presa

{"title":"Cost-effectiveness of microaxial flow pump versus standard of care in the management of Cardiogenic shock in Spain.","authors":"Rut Andrea, Alfonso Jurado-Román, Sandra O Rosillo, Juan Bustamante-Munguira, Jose F Diaz, Maria Generosa Crespo-Leiro, Rocío González-Alonso Del Hoyo, Itziar Oyagüez, Nuria Garcia, Lorine Foux, Stylianos Tsintzos, Maria Presa","doi":"10.1080/14737167.2026.2743886","DOIUrl":"10.1080/14737167.2026.2743886","url":null,"abstract":"Background: Cardiogenic shock (CS) remains the leading cause of death in patients with ST-elevation myocardial infarction (STEMI) despite timely revascularization and advances in pharmacological therapy. This study assessed the cost-effectiveness of a microaxial flow pump (mAFP) plus standard of care (SoC) versus SoC alone in patients with STEMI complicated by CS from the perspective of the Spanish National Health System (NHS).Research design and methods: A cost-effectiveness analysis was conducted using a partitioned survival model over a lifetime horizon. Clinical efficacy inputs were derived from DanGer Shock trial, while adverse and long-term clinical events were obtained from DanGer Shock and literature. Direct healthcare costs (expressed in 2025 euros), including device acquisition, hospitalization, adverse and clinical events management, and cardiac rehabilitation.Results: In the base-case analysis, mAFP+SoC yielded 3.430 life-years gained (LYG) and 2.645 quality-adjusted life-years (QALY) per patient, compared with 1.657 LYG and 1.272 QALYs with SoC alone. Total costs were €51,980 and €17,008, respectively, resulting in an incremental cost-utility ratio of 25,468/QALY. Deterministic and probabilistic sensitivity analyses supported model robustness.Conclusions: From the Spanish NHS perspective, mAFP+SoC could be a cost-effective strategy for STEMI-CS, providing substantial gains in survival and health-related quality of life at a reasonable incremental cost.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of RIMS1 methylation-guided gastric cancer surveillance after Helicobacter pylori eradication. 幽门螺杆菌根除后RIMS1甲基化引导胃癌监测的成本-效果

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-11 DOI: 10.1080/14737167.2026.2746232

Yifan Qiu, Xianzhu Zhou, Hao Hu, Shudan Chen, Xinhui Zhan, Jingmin Feng, Xinyi Cai, Tuo Li, Jing Zhang, Yiqi Du, Jiafeng Zhang

{"title":"Cost-effectiveness of RIMS1 methylation-guided gastric cancer surveillance after Helicobacter pylori eradication.","authors":"Yifan Qiu, Xianzhu Zhou, Hao Hu, Shudan Chen, Xinhui Zhan, Jingmin Feng, Xinyi Cai, Tuo Li, Jing Zhang, Yiqi Du, Jiafeng Zhang","doi":"10.1080/14737167.2026.2746232","DOIUrl":"10.1080/14737167.2026.2746232","url":null,"abstract":"Background: The cost-effectiveness of methylation-guided surveillance after Helicobacter pylori eradication remains uncertain.Research design and methods: From a healthcare system perspective, a cohort model compared annual, biennial, and RIMS1 methylation-guided surveillance over 30 years in Japanese patients aged 50 years with open-type gastric atrophy. Differences in stage at diagnosis were calibrated from annual-surveillance data. Costs and quality-adjusted life-years (QALYs) were discounted at 3.0% annually. Sensitivity analyses examined uncertainty; an exploratory analysis used Korean inputs.Results: At US$52,037.74/QALY, methylation-guided surveillance had the highest net monetary benefit (NMB). Compared with biennial surveillance, its incremental cost-effectiveness ratio was US$47,021.24/QALY and incremental NMB was US$62.56/person. It reduced routine endoscopies by 40.9% versus annual surveillance. Cost-effectiveness varied with surveillance duration, endoscopy-related utility loss, implementation costs, and risk misclassification. Across 5,000 probabilistic draws, methylation-guided surveillance had the highest mean NMB, but biennial surveillance was more often optimal (51.2% vs 36.0%). The preferred strategy in the Korean analysis varied with endoscopy costs.Conclusions: In the base-case analysis, RIMS1-guided surveillance was cost-effective, increasing QALYs compared with biennial surveillance and reducing endoscopy use compared with annual surveillance. Its estimated cost-effectiveness depends on the assumed improvement in stage at diagnosis with more frequent surveillance.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wholesale, pharmacy mark-up, and retail price dynamics under a declaration-based medicine pricing reform in Kosovo. 科索沃基于声明的药品定价改革下的批发、药房加价和零售价格动态。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-10-09 DOI: 10.1080/14737167.2026.2746142

Toskë Kryeziu, Mimoza Basholli Salihu, Venesa Lupçi, Ufuk Bağcı, Aida Loshaj Shala

{"title":"Wholesale, pharmacy mark-up, and retail price dynamics under a declaration-based medicine pricing reform in Kosovo.","authors":"Toskë Kryeziu, Mimoza Basholli Salihu, Venesa Lupçi, Ufuk Bağcı, Aida Loshaj Shala","doi":"10.1080/14737167.2026.2746142","DOIUrl":"10.1080/14737167.2026.2746142","url":null,"abstract":"Background: Medicines' price control is commonly employed to enhance price transparency and affordability; however, empirical evidence on its effects following first-time implementation in European markets with developing pharmaceutical regulatory frameworks remains limited.Research design and methods: This repeated cross-sectional analysis of administrative databases evaluated the official Kosovo medicine price list, consisting of 19 published price-list versions (V1.0, Feb 2025 to V1.18, 25 June 2026), focusing on version-specific changes in final wholesale and retail prices.Results: A total of 69,683 medicine-version records and 5,720 unique products were identified. Among 1,937 medicines included in both V1.0 and V1.18, the wholesale price rose in 1,088 cases (56.17%), fell in 501 (25.86%) cases, and remained unchanged in 348 (17.97%). The retail price increased in 1,205 cases (62.21%), declined in 697 (35.98%), and remained stable in 35 cases (1.81%). The concordance between retail and wholesale price direction was observed in 1,535 cases (79.25%).Conclusions: The price-leveling worked more like a recalibration of the regulatory system based on declarations than a consistent reduction of prices, involving concurrent adjustments, removals, and additions in the price list as well as some retail-level discordances driven by the regulated pharmacy mark-up and value-added tax (VAT) rules.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0